Alignment Healthcare, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALHC research report →
Range $9 – $19
Price Chart
About the company
Alignment Healthcare, Inc. is a technology-driven Medicare Advantage provider operating a healthcare platform focused squarely on the consumer. This organization delivers personalized medical services across the United States, primarily for elderly individuals and others requiring specific support, leveraging its suite of Medicare Advantage plans.
- CEO
- John E. Kao
- IPO
- 2021
- Employees
- 1,849
- HQ
- Orange, CA, US
Get TickerSpark's AI analysis on ALHC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.33B
- P/E
- 45.24
- Fwd P/E
- 41.28
- PEG
- 0.01
- P/S
- 0.27
- P/B
- 4.79
- EV/EBITDA
- 12.45
- Div Yield
- 0.00%
- Gross Margin
- 11.93%
- Op Margin
- 0.88%
- Net Margin
- 0.59%
- ROE
- 12.46%
- ROIC
- 7.16%
Latest fiscal year · YoY change
- Revenue
- $3.95B+46.1%
- Gross Profit
- $488.56M+64.7%
- Op Income
- $14.75M
- Net Income
- $-724,000+99.4%
- EPS
- $-0.00+99.4%
- OCF Growth
- +302.4%
- FCF Growth
- +1802.0%
- 52W High
- $25.12
- 52W Low
- $6.01
- 50D MA
- $8.05
- 200D MA
- $15.66
- Beta
- 1.04
- RSI (14)
- 32
- Avg Volume
- 8.19M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Alignment Healthcare posted strong Q3 membership and revenue growth, but higher medical cost volatility and provider disputes forced a sharp cut to full-year guidance and management is now focused on stabilizing trends ahead of 2027.· October 29, 2026
- Q3 membership reached 301,200, up 31% year over year, and revenue was approximately $1.4 billion, up 37%.
- Adjusted gross profit was $142 million, with adjusted MBR at 89.5% and adjusted SG&A at $120 million, or 8.9% of revenue.
- Adjusted EBITDA came in at $22 million, but management said higher claims volatility, provider appeals/disputes, and SNF/catastrophic costs pressured results.
- Full-year 2026 guidance was cut to at least $5.25 billion of revenue, $575 million of adjusted gross profit, and $100 million of adjusted EBITDA.
- Management said Q4 guidance assumes elevated medical claims continue and is being set conservatively, while they still see at least 20% membership growth potential in 2027.
For Q3 2026, membership was 301,200, up 31% year over year; revenue was approximately $1.4 billion, up 37% year over year; adjusted gross profit was $142 million; adjusted MBR was 89.5%, up 240 basis points year over year; adjusted SG&A was $120 million, or 8.9% of revenue, down 70 basis points year over year; and adjusted EBITDA was $22 million, with an adjusted EBITDA margin of 1.6%. For the first nine months of 2026, operating cash flow was $158 million and cash, cash equivalents and short-term investments were $743 million. For Q4 2026, the company expects membership of no less than 305,000, revenue of no less than $1.32 billion, adjusted gross profit of no less than $104 million, and adjusted EBITDA of no less than negative $28 million. Full-year 2026 guidance is at least $5.25 billion of revenue, $575 million of adjusted gross profit, and $100 million of adjusted EBITDA.
John Kao framed the quarter as one where growth remained strong but medical cost volatility and provider behavior created a temporary setback. He said the company responded with payment integrity edits, tighter post-pay review, and more disciplined clinical management, and noted that appeals had already dropped significantly in August, September, and October. He sounded confident that the company understands the issues, is taking decisive action, and is positioning itself for 2027 growth while balancing margin discipline.
Jim Head highlighted the quarter’s core financials and the balance sheet: $142 million of adjusted gross profit, 89.5% adjusted MBR, $120 million of adjusted SG&A, and $22 million of adjusted EBITDA. He said the company generated $158 million of operating cash flow in the first nine months and ended Q3 with $743 million in cash, cash equivalents and short-term investments, with funded leverage at 2.4x trailing 12 months EBITDA. On guidance, he said Q4 assumes continued elevated medical claims, continued appeals/disputes at a peak rate, ongoing SNF length-of-stay and catastrophic case pressure, and no benefit from payment integrity or clinical initiatives, all while incorporating higher AEP-related SG&A.
Analysts focused heavily on what caused the jump in medical costs and whether the new claims system, Facets, exposed or created the issue. Management said Facets is an industry-leading adjudication platform, but the conversion created volatility in paid claims and timing differences; once the company saw higher appeals and disputes, it made changes and now says those appeals have dropped meaningfully. Another major theme was 2027 pricing and bid calibration: management said bids were reviewed product-by-product and market-by-market, some products or networks were adjusted, and investors should not annualize Q4 MBR as a starting point for 2027. Questions also centered on Stars remediation and California concentration, with management saying the shortfall was driven by HOS, Part D, and cut points, and that provider and member engagement efforts are already underway.
The company still delivered 31% membership growth and 37% revenue growth in Q3, and management reiterated confidence in at least 20% membership growth for 2027. Leadership said claims volatility is stabilizing, appeals/disputes are coming down, and the company has already taken actions on payment integrity, clinical operations, and Stars. Management also pointed to strong liquidity, improving control over utilization, and new provider relationships and market expansion plans as longer-term positives.
Management openly said the quarter exposed higher medical cost trends from provider appeals/disputes, SNF, and catastrophic cases, and it cut full-year guidance as a result. Q4 guidance assumes those pressures persist at near-peak levels, and the company is not giving itself credit for benefits from initiatives already underway, which suggests near-term uncertainty remains high. Stars also remain a risk, especially the California HMO’s 3.5-star result, and management acknowledged that more work is needed to fix HOS, Part D, and provider alignment.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.8%
- Shares Outstanding
- 209.27M
- Float Shares
- 190.04M
of shares held by institutions
338 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 25.25M | ▲ 5.91M |
| Wellington Management Group Llp | 16.49M | ▼ 2.29M |
| Vanguard Group Inc | 15.49M | ▲ 1.52M |
| Vanguard Portfolio Management LLC | 10.74M | ▼ 933.69K |
| T. Rowe Price Investment Management, Inc. | 9.48M | ▼ 3.64M |
| Fmr LLC | 8.69M | ▼ 5.23M |
| Vanguard Capital Management LLC | 8.40M | ▲ 250.89K |
| State Street Corp | 7.90M | ▲ 603.93K |
| William Blair Investment Management, LLC | 6.25M | ▼ 1.51M |
| Bank Of America Corp | 5.96M | ▼ 3.39M |
| Capital Research Global Investors | 5.74M | ▲ 1.34M |
| Geode Capital Management, LLC | 4.61M | ▼ 230.59K |
Held by 420 ETFs
Biggest fund positions in ALHC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | KONOWIECKI JOSEPH S | sell | 4,930 |
| Oct 6, 26 | Kim Hyong | sell | 32,479 |
| Sep 17, 26 | KONOWIECKI JOSEPH S | sell | 23,511 |
| Sep 14, 26 | KAO JOHN E | sell | 27,400 |
| Sep 11, 26 | Maroney Dawn Christine | sell | 122,707 |
| Sep 11, 26 | KAO JOHN E | sell | 385,270 |
| Sep 10, 26 | KAO JOHN E | sell | 172,600 |
| Aug 14, 26 | Maroney Dawn Christine | sell | 5,000 |
| Aug 10, 26 | KAO JOHN E | sell | 298,000 |
| Jul 15, 26 | Maroney Dawn Christine | other | 152,068 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ALHC coverage
Recent articles, reports, and earnings notes.
No research on ALHC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALHC report →ALHC Investors: BFA Law Notifies Alignment Healthcare Investors with Losses of its Ongoing Securities Fraud Investigation
globenewswire.com · Nov 20
Alignment Healthcare (NASDAQ: ALHC) Increasingly Scrutinized Over H3815 Cut Points And CMS Bonus Eligibility - Hagens Berman
prnewswire.com · Nov 19
Alignment Healthcare Investors Should Contact Block & Leviton to Possibly Recover Losses
newsfilecorp.com · Nov 18
ALHC Investigation: Alignment Healthcare is being Investigated for Securities Fraud Following Inflated EBITDA Allegations – Contact BFA Law if You Lost Money
globenewswire.com · Nov 18
ALHC Loss Alert: Alignment Healthcare Investors Investigated for Securities Fraud in Connection with 16% Stock Drop and Potential Misrepresentations about its EBITDA
prnewswire.com · Nov 17
ALHC Investors Have Opportunity to Join Alignment Healthcare, Inc. Fraud Investigation with SBS Law
businesswire.com · Nov 17
ALHC Investors Have Opportunity to Join Alignment Healthcare, Inc. Fraud Investigation with the Schall Law Firm
prnewswire.com · Nov 16
Alignment Healthcare Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alignment Healthcare, Inc. - ALHC
businesswire.com · Nov 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.